<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01464840</url>
  </required_header>
  <id_info>
    <org_study_id>F101111007</org_study_id>
    <nct_id>NCT01464840</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetics of Azithromycin Prophylaxis for Cesarean Delivery</brief_title>
  <acronym>PKAZ</acronym>
  <official_title>The Pharmacokinetics of Azithromycin Prophylaxis for Cesarean Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PKAZ is a single institution study designed to evaluate the optimal dosing parameters for
      azithromycin for pre-surgical cesarean prophylaxis.

      Hypothesis: Pre-operative administration of azithromycin results in maternal and neonatal
      tissue concentrations that adequately treat microbes commonly involved in post-cesarean
      infections.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients in Each Group That Attain an Adequate Azithromycin Concentration</measure>
    <time_frame>48 hours after delivery</time_frame>
    <description>The primary outcome of this study will be the number of patients in each group that attain an azithromycin concentration in the various maternal and fetal tissues at least equivalent to the MIC 90 for common organisms involved in post-cesarean infections.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Endometritis</condition>
  <arm_group>
    <arm_group_label>15 minutes</arm_group_label>
    <description>500 mg of intravenous azithromycin will be administered 15 minutes prior to incision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 minutes</arm_group_label>
    <description>500 mg of intravenous azithromycin will be administered 30 minutes prior to incision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60 minutes</arm_group_label>
    <description>500 mg of intravenous azithromycin will be administered 60 minutes prior to incision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>500 mg intravenous infused over 1 hour</description>
    <arm_group_label>15 minutes</arm_group_label>
    <arm_group_label>30 minutes</arm_group_label>
    <arm_group_label>60 minutes</arm_group_label>
    <other_name>Zmax</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Maternal blood, maternal adipose tissue, maternal myometrium, maternal breast milk, amniotic
      fluid, and fetal cord blood.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women 19 years and older undergoing scheduled cesearean sections
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women 19 years and older

          -  Term (37 weeks and greater)

          -  Singleton gestation

          -  Scheduled cesarean section

          -  Non-laboring

          -  Intact membranes

        Exclusion Criteria:

          -  &lt; 19 years of age

          -  Preterm (&lt; 37 weeks)

          -  Multifetal gestation

          -  Laboring or ruptured membranes

          -  Known fetal anomaly

          -  Oligo- or polyhydramnios

          -  Macrolide allergy

          -  Macrolide exposure within 2 weeks

          -  Medical co-morbidities

          -  Hepatic or renal impairment

          -  Taking medications that prolong the QT interval

          -  Currently taking nelfinavir, efavirenz, or flucanozole

          -  Structural heart defects or arrythmia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amelia L Sutton, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2011</study_first_submitted>
  <study_first_submitted_qc>November 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2011</study_first_posted>
  <results_first_submitted>November 2, 2013</results_first_submitted>
  <results_first_submitted_qc>November 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 9, 2014</results_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Amelia Sutton, MD, PhD</investigator_full_name>
    <investigator_title>Fellow/Instructor, Maternal Fetal Medicine</investigator_title>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>Cesarean section</keyword>
  <keyword>Antibiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometritis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from the prenatal clinic from May 2012 to May 2013.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>15 Minutes</title>
          <description>500 mg of intravenous azithromycin will be administered 15 minutes prior to incision.
Azithromycin : 500 mg intravenous infused over 1 hour</description>
        </group>
        <group group_id="P2">
          <title>30 Minutes</title>
          <description>500 mg of intravenous azithromycin will be administered 30 minutes prior to incision.
Azithromycin : 500 mg intravenous infused over 1 hour</description>
        </group>
        <group group_id="P3">
          <title>60 Minutes</title>
          <description>500 mg of intravenous azithromycin will be administered 60 minutes prior to incision.
Azithromycin : 500 mg intravenous infused over 1 hour</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>15 Minutes</title>
          <description>500 mg of intravenous azithromycin will be administered 15 minutes prior to incision.
Azithromycin : 500 mg intravenous infused over 1 hour</description>
        </group>
        <group group_id="B2">
          <title>30 Minutes</title>
          <description>500 mg of intravenous azithromycin will be administered 30 minutes prior to incision.
Azithromycin : 500 mg intravenous infused over 1 hour</description>
        </group>
        <group group_id="B3">
          <title>60 Minutes</title>
          <description>500 mg of intravenous azithromycin will be administered 60 minutes prior to incision.
Azithromycin : 500 mg intravenous infused over 1 hour</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" spread="4"/>
                    <measurement group_id="B2" value="27" spread="5"/>
                    <measurement group_id="B3" value="29" spread="6"/>
                    <measurement group_id="B4" value="28" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients in Each Group That Attain an Adequate Azithromycin Concentration</title>
        <description>The primary outcome of this study will be the number of patients in each group that attain an azithromycin concentration in the various maternal and fetal tissues at least equivalent to the MIC 90 for common organisms involved in post-cesarean infections.</description>
        <time_frame>48 hours after delivery</time_frame>
        <population>No patients had azithromycin concentrations at least equivalent to the MIC 90.</population>
        <group_list>
          <group group_id="O1">
            <title>30 Minutes</title>
            <description>500 mg of intravenous azithromycin will be administered 30 minutes prior to incision.
Azithromycin : 500 mg intravenous infused over 1 hour</description>
          </group>
          <group group_id="O2">
            <title>15 Minutes</title>
            <description>500 mg of intravenous azithromycin will be administered 15 minutes prior to incision.
Azithromycin : 500 mg intravenous infused over 1 hour</description>
          </group>
          <group group_id="O3">
            <title>60 Minutes</title>
            <description>500 mg of intravenous azithromycin will be administered 60 minutes prior to incision.
Azithromycin : 500 mg intravenous infused over 1 hour</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients in Each Group That Attain an Adequate Azithromycin Concentration</title>
          <description>The primary outcome of this study will be the number of patients in each group that attain an azithromycin concentration in the various maternal and fetal tissues at least equivalent to the MIC 90 for common organisms involved in post-cesarean infections.</description>
          <population>No patients had azithromycin concentrations at least equivalent to the MIC 90.</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>15 Minutes</title>
          <description>500 mg of intravenous azithromycin will be administered 15 minutes prior to incision.
Azithromycin : 500 mg intravenous infused over 1 hour</description>
        </group>
        <group group_id="E2">
          <title>30 Minutes</title>
          <description>500 mg of intravenous azithromycin will be administered 30 minutes prior to incision.
Azithromycin : 500 mg intravenous infused over 1 hour</description>
        </group>
        <group group_id="E3">
          <title>60 Minutes</title>
          <description>500 mg of intravenous azithromycin will be administered 60 minutes prior to incision.
Azithromycin : 500 mg intravenous infused over 1 hour</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amelia Sutton, M.D., Ph.D.</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-934-5612</phone>
      <email>alsutton@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

